Affordable Access

deepdyve-link
Publisher Website

Mechanistic Models of Signaling Pathways Reveal the Drug Action Mechanisms behind Gender-Specific Gene Expression for Cancer Treatments.

Authors
  • Çubuk, Cankut1, 2, 3
  • Can, Fatma E1, 4
  • Peña-Chilet, María1, 5, 6
  • Dopazo, Joaquín1, 5, 6, 7
  • 1 Clinical Bioinformatics Area. Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013 Sevilla, Spain. , (Spain)
  • 2 Division of Genetics and Epidemiology, Institute of Cancer Research, London, SW7 3RP, UK.
  • 3 William Harvey Research Institute, Queen Mary University, London, EC1M 6BQ, UK.
  • 4 Department of Biostatistics, Faculty of Medicine, Izmir Katip Celebi University, Balatçık, 35620, Turkey. , (Turkey)
  • 5 Bioinformatics in Rare Diseases (BiER). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, 41013 Sevilla, Spain. , (Spain)
  • 6 Computational Systems Medicine, Institute of Biomedicine of Seville (IBIS), 41013 Sevilla, Spain. , (Spain)
  • 7 FPS-ELIXIR-ES, Hospital Virgen del Rocío, 41013 Sevilla, Spain. , (Spain)
Type
Published Article
Journal
Cells
Publisher
MDPI AG
Publication Date
Jun 29, 2020
Volume
9
Issue
7
Identifiers
DOI: 10.3390/cells9071579
PMID: 32610626
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Despite the existence of differences in gene expression across numerous genes between males and females having been known for a long time, these have been mostly ignored in many studies, including drug development and its therapeutic use. In fact, the consequences of such differences over the disease mechanisms or the drug action mechanisms are completely unknown. Here we applied mechanistic mathematical models of signaling activity to reveal the ultimate functional consequences that gender-specific gene expression activities have over cell functionality and fate. Moreover, we also used the mechanistic modeling framework to simulate the drug interventions and unravel how drug action mechanisms are affected by gender-specific differential gene expression. Interestingly, some cancers have many biological processes significantly affected by these gender-specific differences (e.g., bladder or head and neck carcinomas), while others (e.g., glioblastoma or rectum cancer) are almost insensitive to them. We found that many of these gender-specific differences affect cancer-specific pathways or in physiological signaling pathways, also involved in cancer origin and development. Finally, mechanistic models have the potential to be used for finding alternative therapeutic interventions on the pathways targeted by the drug, which lead to similar results compensating the downstream consequences of gender-specific differences in gene expression.

Report this publication

Statistics

Seen <100 times